LLY vs VKTX
LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | LLY | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1,163.01 | $37.31 | |
| Market cap as of 2026-07-23 | $1.09T | $4.3B | |
| P/E as of 2026-07-23 | 43.27 | n/a | |
| PEG as of 2026-07-23 | 1.37 | -0.04 | VKTX lower |
| Net margin as of 2026-07-23 | +35.0% | n/a | |
| Gross margin as of 2026-07-23 | +82.8% | n/a | |
| Operating margin as of 2026-07-23 | +43.6% | n/a | |
| ROE as of 2026-07-23 | +101.3% | -71.3% | LLY higher |
| ROA as of 2026-07-23 | +22.7% | -65.3% | LLY higher |
| Debt / equity as of 2026-07-23 | 1.39 | 0.00 | VKTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +47.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +31.7% | n/a | |
| Dividend yield as of 2026-07-23 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.51 | 0.65 | |
| 1-year return as of 2026-07-22 close | +49.8% | +16.2% | LLY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.